Patents for A61P 35 - Antineoplastic agents (221,099)
07/2005
07/20/2005CN1211089C Application of uridine phosphorylase inhibitor and composition containing the same
07/20/2005CN1211088C Application of emodin analog EMD-31 for treating tumor
07/20/2005CN1211083C Sophoridine and its application in analgesic
07/19/2005US6919461 Anticancer agents; antiarthritic agents
07/19/2005US6919435 Comprises cancer marker glycoprotein for diagnosis of stomach, colon and breast cancers
07/19/2005US6919425 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
07/19/2005US6919424 Comprises polypeptide for, diagnosis, detection and treatment of cancer
07/19/2005US6919370 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
07/19/2005US6919362 For use as hypoglycaemic and hypolipidaemic agents
07/19/2005US6919353 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents
07/19/2005US6919343 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
07/19/2005US6919341 Imidazo(1,2-a)pyrazine compounds
07/19/2005US6919340 Kinase moderators; controlling gene expression; immunosuppressants; autoimmune disease; rheumatic disorders; skin disorders; antitumor agents; anticancer agents
07/19/2005US6919338 Antiproliferative agents; anticancer agents
07/19/2005US6919335 Heterocycles that are inhibitors of IMPDH enzyme
07/19/2005US6919332 Enzyme inhibitors such as 5-(2-Methoxy-ethyl)-5-(4-(1-pyridin -3-yl-1H-indazol-5-yloxy)-phenoxy)-pyrimidine-2,4,6-trione, used as antiinflammatory and anticarcinogenic agents
07/19/2005US6919327 Texaphyrin coordination compounds and uses thereof
07/19/2005US6919324 Functionalized stilbene derivatives as improved vascular targeting agents
07/19/2005US6919307 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
07/19/2005US6919206 Medium containing flt3 ligand for culturing hematophoietic cells
07/19/2005US6919081 Lak activity potentiator orginating in shitake mushroom hyphae extract and lak activity potentiating preparations containing the same
07/19/2005US6919079 FcεPE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same
07/19/2005US6919075 Bacteriophage displaying aβ epitopes and method of use
07/19/2005US6918927 Coated implantable medical device
07/15/2005WO2004068143A1 Use of substances inhibiting the association of smad protein with ubiquitin c-terminal hydrolase for altering cellular responses to tgf-beta or bmp
07/15/2005CA2513593A1 Use of substances inhibiting the association of smad protein with ubiquitin c-terminal hydrolase for altering cellular responses to tgf-beta or bmp
07/14/2005WO2005063820A2 Il-7 fusion proteins
07/14/2005WO2005063801A2 Method for decreasing the contact between hepta-repeat region s of the corona-virus spike proteins and use thereof
07/14/2005WO2005063725A1 Phenylpropanoic acid derivatives
07/14/2005WO2005063720A1 Amide derivative and medicine
07/14/2005WO2005063280A1 Allogeneic tumor therapeutic agent
07/14/2005WO2005063227A1 Process for producing triterpene composition
07/14/2005WO2005062748A2 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae
07/14/2005WO2005009480A3 Implants containing codrugs
07/14/2005WO2004063024A3 Floral packaging material having prints thereon
07/14/2005WO2004060270A8 Compositions and methods for the diagnosis and treatment of tumor
07/14/2005WO2004048386A9 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS
07/14/2005WO2004017923A3 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
07/14/2005WO2003082212A3 Method for treating cancer in humans
07/14/2005WO2003059294A3 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
07/14/2005WO2003029424A3 Novel proteins and nucleic acids encoding same
07/14/2005US20050155089 Transport protein for use in identifying modulators for prevention and treatment of inflammation, cardiovascular, neurological, reproductive and developmental disorders
07/14/2005US20050155087 Method of screening compounds
07/14/2005US20050154187 Especially fused to dihydrofolate reductase, used for treating diseases marked by increased angiogenesis; also polynucleotides encoding the polypeptide and use of the polynucleotides in gene therapy.
07/14/2005US20050154165 Ph-sensitive polymer
07/14/2005US20050154062 Substituted chiral allosteric hemoglobin modifiers
07/14/2005US20050154049 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis
07/14/2005US20050154039 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
07/14/2005US20050154019 Substituted cyclic amine metalloprotease inhibitors
07/14/2005US20050154015 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
07/14/2005US20050154012 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
07/14/2005US20050154005 Administering to a subject in need of such treatment an effective amount of 1,1'-[1,4-(phenylenebis(methylene))]bis-1,4,8,11-tetraazacyclotetradecane or a pharmaceutical composition thereof, wherein the inhibition of CXCR4 receptor binding effects treatment or amelioration of said condition
07/14/2005US20050154004 4-Phenyl-6H-(1)Benzopyrano(4',3':4,5)pyrrolo(2,1-a)isoquinolin-6-one's and analogues, optionally mixed with acceptable carriers, excipients or diluents, used for treating multidrug resistant tumors, for inducing apoptosis and as immunology modulators
07/14/2005US20050154003 Containing a 1H,3H-furo[3',4':6,7]indolizino[1,2-b]quinoline ring, e.g., {10-[(E)-(ter-butoxyimino)methyl]-3-ethyl-1,13-dioxo-11,13-dihydro-1H,3H-furo[3',4':6,7]indolizino[1,2-b]quinolin-3-yl}acetic acid; topoisomerase I inhibitors used to treat cancer
07/14/2005US20050153997 Fredericamycin derivatives
07/14/2005US20050153996 Compounds that modulate ppar activity and methods for their preparation
07/14/2005US20050153992 Glycogen synthase kinase-3 inhibitors; pyrrolo[3,2-d]pyrimidine: neurodegenerative diseases; antidiabetic, antiinflammatory, anticancer agents; 5-(2-aminoethyl)-6-(3-chloro(2-thienyl))-7-iodo-3-hydropyrrolo[3,2-d]pyrimidin-4-thione Trifluoroacetate; 4-halo intermediates
07/14/2005US20050153991 Methods of treatment of chronic lymphocytic leukemia using roscovitine
07/14/2005US20050153975 Y823D, N822K or D816H mutations in the c-Kit tyrosine kinase; antitumour agent; alternative to radiation or chemotherapy; reduce consequent infertility; good tolerability of compound mesylate treatment; no drug-related liver, renal or cardiac toxicity
07/14/2005US20050153973 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes
07/14/2005US20050153965 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
07/14/2005US20050153960 Substituted arylamine derivatives and methods of use
07/14/2005US20050153920 Ribozymes used as prodrugs
07/14/2005US20050153917 Gene overexpression/underexpression; antibodies; drug screening; kits
07/14/2005US20050153902 Inhibitors of integrin avb6
07/14/2005US20050153878 Fgfr agonists
07/14/2005US20050153440 Using embryonic germ cell as model for monittoring and evaluating genomic imprinting; tissue engineering; tissue targeted therapy; regenerative medicine; gene silencing
07/14/2005US20050153416 Anticancer agents
07/14/2005US20050153372 Using calmodulin-dependent protein kinase and/or calcineurin as tool in detecting modulators of nervous system and brain disorders; enzyme inhibitors
07/14/2005US20050153332 Method of diagnosing, monitoring, staging, imaging and treating colon cancer
07/14/2005US20050153330 Novel DKR polypeptides
07/14/2005US20050153315 Nucleotide sequences coding polypeptide comprising methylarginase activities for use in identifying modulator for prevention and treatment of ischemia-reperfusion injuries, cancer, hypotension, multi-organ failure, arthritis, skin, inflammatory, cardiac and/or migraine disorders
07/14/2005US20050153289 Method of analyzing gene expression
07/14/2005US20050153286 Calcium channel polypeptide for use in identifying modulator for prevention and treatment of cell proliferative disorders of the kidney
07/14/2005US20050152959 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
07/14/2005US20050152930 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
07/14/2005US20050152926 For immunization and/or diagnosis; eg pneumonia, cardiovascular diseases, atherosclerosis, bronchitis
07/14/2005US20050152921 Modified CpG oligodeoxynucleotide with improved immunoregulatory function
07/14/2005US20050152916 Antigen presenting system and methods for activation of T-cells
07/14/2005US20050152915 Exposure of tumor cells obtained ex vivo or pathological cells of a non-tumorous nature or of a biological fluid of a mammal containing viruses or bacteria to radiation of the optical range, the administering them into the lymphatic system ; enhances the efficacy and usability of immunotherapy
07/14/2005US20050152913 Process for preapring maytansinol
07/14/2005US20050152909 Prostate stem cell antigen (PSCA) tumor antigen for use in diagnosis, prevention and treatment of prostate cancers
07/14/2005US20050152894 Antibodies with altered effector functions
07/14/2005US20050152878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
07/14/2005US20050152874 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells
07/14/2005DE10018681B4 Therapeutisches Mittel für die autologe Immuntherapie von Tumoren sowie Verfahren zur Herstellung eines solchen Mittels A therapeutic agent for autologous immunotherapy of tumors as well as methods for preparing such an agent
07/14/2005CA2552095A1 Novel crystalline forms of temozolomide
07/14/2005CA2551915A1 Il-7 fusion proteins
07/14/2005CA2551100A1 Compositions and methods for combined therapy of disease
07/14/2005CA2550998A1 Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
07/14/2005CA2550686A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
07/14/2005CA2549652A1 Cd40 antibody formulation and methods
07/13/2005EP1553178A1 Tumor-lysing virus growing selectively in tumor cells
07/13/2005EP1553176A1 Apparatus for introducing biological material, method of introducing biological material and magnetic support for introducing biological material
07/13/2005EP1553168A2 Methods for selectively stimulating proliferation of T cells
07/13/2005EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
07/13/2005EP1553097A1 Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore
07/13/2005EP1553080A1 Use of cyclic depsipeptide as a chemotherapeutic agent against cancer
07/13/2005EP1553078A1 Calcium receptor-active compounds
07/13/2005EP1553074A1 Fused benzene derivative and use